230 related articles for article (PubMed ID: 3088040)
1. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
Colucci M; Paramo JA; Stassen JM; Collen D
J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
[TBL] [Abstract][Full Text] [Related]
2. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
[TBL] [Abstract][Full Text] [Related]
4. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D
Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173
[TBL] [Abstract][Full Text] [Related]
5. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.
Colucci M; Paramo JA; Collen D
J Lab Clin Med; 1986 Jul; 108(1):53-9. PubMed ID: 3086473
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
Shohet RV; Spitzer S; Madison EL; Bassel-Duby R; Gething MJ; Sambrook JF
Thromb Haemost; 1994 Jan; 71(1):124-8. PubMed ID: 8165630
[TBL] [Abstract][Full Text] [Related]
8. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Paloma MJ; Páramo JA; Rocha E
Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
[TBL] [Abstract][Full Text] [Related]
9. Fibrin-specific thrombolytic agents.
Collen D
Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
[TBL] [Abstract][Full Text] [Related]
10. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
11. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
12. [Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value].
Korninger C
Wien Klin Wochenschr; 1985 Nov; 97(22):832-40. PubMed ID: 2934899
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits.
Krishnamurti C; Barr CF; Hassett MA; Young GD; Alving BM
Blood; 1987 Mar; 69(3):798-803. PubMed ID: 3101764
[TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
17. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.
Kruithof EK; Tran-Thang C; Bachmann F
Thromb Haemost; 1986 Feb; 55(1):65-9. PubMed ID: 3085266
[TBL] [Abstract][Full Text] [Related]
18. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]